Compugen Ltd. (CGEN)
| Market Cap | 794.36M |
| Revenue (ttm) | 2.00M |
| Net Income (ttm) | -29.70M |
| Shares Out | 79.59M |
| EPS (ttm) | -0.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 3 |
| Last Price | $8.91 |
| Previous Close | $9.41 |
| Change ($) | -0.50 |
| Change (%) | -5.31% |
| Day's Open | 9.56 |
| Day's Range | 8.66 - 9.67 |
| Day's Volume | 1,424,772 |
| 52-Week Range | 5.94 - 19.90 |
ARK Investment Management – or ARK Invest, as it usually styles itself – had a great 2020. ARK Innovation ETF (ARKK), the firm's flagship fund, returned more than 150% last year.
Compugen Ltd (NASDAQ: CGEN) reports updated data from its Phase 1 dose-escalation and expansion study of COM701 as a monotherapy and a dose-escalation combination study with Bristol-Myers Squi...
HOLON, Israel, Feb. 25, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial r...
Compugen Ltd (NASDAQ: CGEN) expands its clinical collaboration agreement with Bristol-Myers Squibb Co (NYSE: BMY), wherein Bristol Myers will supply Opdivo (nivolumab) for Compugen's Phase 1b ...
HOLON, Israel, Dec. 23, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today progress f...
HOLON, Israel, Nov. 10, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that managem...
Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q3 2020 Results - Earnings Call Transcript
HOLON, Israel, Sept. 30, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the addit...
HOLON, Israel, Sept. 8, 2020 /PRNewswire/ -- Compugen Ltd.
HOLON, Israel, Sept. 3, 2020 /PRNewswire/ -- Compugen Ltd.
HOLON, Israel, Aug. 28, 2020 /PRNewswire/ -- Compugen Ltd.
Compugen Ltd (CGEN) CEO Anat Dayag on Q2 2020 Results - Earnings Call Transcript
HOLON, Israel, July 30, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial r...
Compugen: Clinical Data Supports COM701 As A Potential Breakthrough Cancer Treatment
HOLON, Israel, July 16, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the C...
Compugen's Cancer Trial, And Other News: The Good, Bad And Ugly Of Biopharma
HOLON, Israel, June 1, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the U....
Here are the hottest companies coming up in the biotech sector next month.
Investors need to pay close attention to Compugen (CGEN) stock based on the movements in the options market lately.
Compugen (CGEN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Roche's Upcoming Phase 2 TIGIT Results At ASCO Could Read Through To Compugen's COM902 TIGIT Candidate
Top Ranked Momentum Stocks to Buy for May 8th
Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q1 2020 Results - Earnings Call Transcript
Its new discovery in the field of cancer immunotherapy produced mixed clinical results, but it certainly has ample backing from the big players.
Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
When the financial markets enter their once-a-decade crisis mode, it often feels impossible to think rationally and to make normal investing decisions.
Two patients treated with one of the biotech's drugs had partial responses.
Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q4 2019 Results - Earnings Call Transcript
Compugen Ltd.: Upcoming Catalysts In 2020 And 2021
With stocks at all time highs and after the Dow rose more than 22% and the S&P 500 rose over 28% in 2019, many investors have yet to make many changes in the portfolios for what could be anoth...
Compugen shares rebounded Thursday after Cantor Fitzgerald initiated coverage with an Overweight rating and a $10 price target.
The biotech sector has had a good run in 2019 on the back of ongoing M&A activities and positive pipeline updates.
Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q3 2019 Results - Earnings Call Transcript
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q2 2019 Results - Earnings Call Transcript
Compugen (CGEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q1 2019 Results - Earnings Call Transcript
About CGEN
Compugen, a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its thera... [Read more...]
| Industry Biotechnology | IPO Date Aug 11, 2000 |
| CEO Dr. Anat Cohen-Dayag | Employees 68 |
| Stock Exchange NASDAQ | Ticker Symbol CGEN |
Analyst Forecasts
According to 6 analysts, the average rating for Compugen stock is "Strong Buy." The 12-month stock price forecast is 21.71, which is an increase of 143.66% from the latest price.